Fig. 3

Bromocriptine attenuates exodosis in skeletal muscle cell line. A Mass spectrometry analysis of media from T0034 skeletal muscle cell line pre-treated with vehicle, 20 µM bromocriptine, or 50 µM dantrolene 30 min prior to 100 nM Tg for 8 h. Solid line represents mean fold change B Extracellular ERS proteins identified from mass spectrometry analysis pre-treated with vehicle, 20 µM bromocriptine, or 50 µM dantrolene 30 min prior to 100 nM Tg for 8 h; solid line represents mean fold change, ****p < 0.0001, 1-way ANOVA, Dunnett’s multiple comparison test, Tg vs bromocriptine or dantrolene. C Extracellular MANF identified by mass spectrometry in media from skeletal muscle cells pre-treated with vehicle, 20 µM bromocriptine, or 50 µM dantrolene 30 min prior to 100 nM Tg for 8 h; mean ± SEM, *p < 0.05, 1-way ANOVA, Dunnett’s multiple comparison test. D Extracellular MANF identified by MANF HTRF assay of media collected from T0034 skeletal muscle cell line pre-treated with vehicle, 3 µM, 10 µM, 20 µM bromocriptine, or 10 µM, 30 µM, 50 µM dantrolene 30 min prior to 100 nM Tg for 8 h; mean ± SEM, n = 6–12 wells/treatment group, *p < 0.05, ***p < 0.001, ****p < 0.0001, 1-way ANOVA, Dunnett’s multiple comparison test, Tg vs other treatment groups. E) Densitometry analysis of western blot of concentrated media collected from T0034 skeletal muscle cell line pre-treated with vehicle, 20 µM bromocriptine, or 50 µM dantrolene, mean ± SEM, n = 2/treatment groups, *p < 0.05, **p < 0.01, 1-way ANOVA, Dunnett’s multiple comparison test vehicle/Tg vs vehicle/vehicle, bromocriptine/Tg, or dantrolene/Tg